BNGO

Bionano Genomics, Inc. BNGO

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,827 of 2,925

Why it scores 14Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$8.17M

Quarter to Jun 30

Net income

$-7.42M

Quarter to Jun 30

Operating margin

-88.3%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$801.6K total
GSA CAPITAL PARTNERS LLP
$170.0K-57.5%
CARRET ASSET MANAGEMENT, LLC
$141.3K+78.6%
GEODE CAPITAL MANAGEMENT, LLC
$101.7K-46.3%
VANGUARD CAPITAL MANAGEMENT LLC
$93.1K+21.0%
VANGUARD FIDUCIARY TRUST CO
$58.3K0.0%
RENAISSANCE TECHNOLOGIES LLC
$57.7K+4.9%
JANE STREET GROUP, LLC
$40.4KNew
PRUDENTIAL FINANCIAL INC
$35.7K+12.9%
NORTHERN TRUST CORP
$27.8K+19.7%
XTX Topco Ltd
$18.4KNew
Engineers Gate Manager LP
$13.5K+1.1%
HRT FINANCIAL LP
$13.0KNew
BlackRock, Inc.
$11.2K0.0%
OSAIC HOLDINGS, INC.
$8.8K+14.8%
Tower Research Capital LLC (TRC)
$5.9KNew
MORGAN STANLEY
$1.2K+11.9%
Concord Wealth Partners
$1.1KNew
GROUP ONE TRADING, L.P.
$1.1K0.0%
UBS Group AG
$918+4975.0%
SBI Securities Co., Ltd.
$278+5.1%
WELLS FARGO & COMPANY/MN
$1280.0%
BNP PARIBAS FINANCIAL MARKETS
$150.0%
JPMORGAN CHASE & CO
$130.0%
Caitong International Asset Management Co., Ltd
$6New
TD Waterhouse Canada Inc.
$60.0%
See all 35 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BNGO

Earnings Per Share

13fpro.ai/company/BNGO

Loading ratio trend…

BNGO key financials by period

Reported revenue, net income and operating margin by fiscal year, from Bionano Genomics, Inc.'s annual filings on SEC EDGAR.

Bionano Genomics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$28.5M$-26.4M-117.0%
FY 2024$30.8M$-112.0M—
FY 2023$36.1M$-232.5M—
FY 2022$27.8M$-132.6M—
FY 2021$18.0M$-72.4M—
FY 2020$8.5M$-41.1M—
Source: BNGO filings on SEC EDGAR →

Companies similar to BNGO

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

BNGO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Bionano Genomics, Inc. (BNGO): stock profile, AI score and financials

Bionano Genomics, Inc. (BNGO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BNGO at 14.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,827 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.3) and revenue scale (5.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Bionano Genomics, Inc. reports quarterly revenue of $8.2M, net income of $-7.4M, an operating margin of -88.3%. Top institutional holders of BNGO by reported 13-F value include GSA CAPITAL PARTNERS LLP, CARRET ASSET MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. BNGO trades on the Nasdaq exchange and files with the SEC under CIK 1411690. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BNGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bionano Genomics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1411690 →